secwatch.observer — SEC 8-K summary
======================================

Issuer:     Decoy Therapeutics Inc. (DCOY)
CIK:        0001615219
Form:       8-K
Filed at:   2024-06-17T23:59:59+00:00
Accession:  0001615219-24-000049
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Salarius reports 43% ORR for seclidemstat combo in MDS/CMML at EHA 2024
-----------------------------------------------------------------------

- Seclidemstat + azacitidine: 43% overall response rate (6/14 evaluable) in higher-risk MDS/CMML patients who failed HMA therapy.
- Median overall survival 18.5 months (95% CI 6.1-30.9) vs typical 4-6 months after HMA failure; median event-free survival 7.2 months.
- Phase 1/2 dose-escalation enrolling Cohort 5 (750mg BID) and planned Cohort 6 (900mg BID); MTD not yet reached.
- Dose-limiting toxicity observed in 1 patient at 750mg BID; cohort expanded per protocol; adverse events deemed manageable.
- Data presented by MD Anderson investigator at European Hematology Association meeting June 13-16, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1615219/000161521924000049/0001615219-24-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1615219/000161521924000049/flks-20240617.htm
  HTML page:      https://secwatch.observer/filing/0001615219-24-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer